Uses of kappa opioid synthetic peptide amides
The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, MMP-1 and MMP-3. Such diseases and conditions include cardiovascular inflammation, neurological inflammation, skeletal inflammation, muscular inflammation, gastrointestinal inflammation, ocular inflammation, otic inflammation, inflammation due to insect bites and inflammation due to wound healing; atherosclerosis, ischemia, restenosis and vasculitis; of asthma, Sjogren's syndrome, pulmonary inflammation, chronic airway inflammation and chronic obstructive pulmonary disease (COPD), allergy, psoriasis, psoriatic arthritis, eczema, scleroderma, atopic dermatitis and systemic lupus erythematosus, arthritis, synovitis, osteomyelitis, rheumatoid arthritis, osteoarthritis and ankylosing spondylitis; septicemia and septic shock, diabetes, glucose intolerance, insulin resistance and obesity, colitis, ulcerative colitis, Crohn's disease, IBD and IBS, and the inflammatory diseases and conditions due to tumor proliferation, tumor metastasis or transplantation rejection.
1. A method of prophylaxis or treatment of kappa opioid receptor-associated pain, or pruritis in a mammal, the method comprising administering to the mammal a composition comprising an effective amount of a synthetic peptide amide of the formula:
or a stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, hydrate, acid salt hydrate or N-oxide thereof,
wherein each Xaa 1 is independently selected from the group consisting of (A)(A′)D-Phe, (A)(A′)(α-Me)D-Phe, D-Tyr, D-Tic, D-tert-leucine, D-neopentyl-glycine, D-phenylglycine, D-homophenylalanine and β-(E)D-Ala, wherein each (A) and each (A′) are phenyl ring substituents independently selected from the group consisting of —H, —F, —Cl, —NO 2 , —CH 3 , —CF 3 , —CN, —CONH 2 , and wherein each (E) is independently selected from the group consisting of cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, thienyl and thiazolyl;
each Xaa 2 is independently selected from the group consisting of (A)(A′)D-Phe, (A)(A′)(α-Me)D-Phe, D-1Nal, D-2Nal, D-Tyr, (E)D-Ala, and D-Trp;
each Xaa 3 is independently selected from the group consisting of D-Nle, D-Phe, (E)D-Ala, D-Leu, (α-Me)D-Leu, D-Hle, D-Val, and D-Met;
each Xaa 4 is independently selected from the group consisting of (B) 2 D-Arg, (B) 2 D-Nar, (B) 2 D-Har, ξ-(B)D-Hlys, D-Dap, ε-(B)D-Lys, ε-(B) 2 -D-Lys, D-Amf, amidino-D-Amf, γ-(B) 2 D-Dbu, δ-(B) 2 α-(B′)D-Orn, D-2-amino -3(4-piperidyl)propionic acid, D-2-amino-3(2-aminopyrrolidyl)propionic acid, D-α-amino-β-amidino-propionic acid, α-amino-4-piperidineacetic acid, cis-α,4-diaminocyclohexane acetic acid, trans-α,4-diaminocyclo-hexaneacetic acid, cis-α-amino-4-methyl-aminocyclo-hexane acetic acid, trans-α-amino-4-methylaminocyclohexane acetic acid, α-amino-1-amidino-4-piperidineacetic acid, cis-α-amino-4-guanidino-cyclohexane acetic acid, and trans-α-amino-4-guanidinocyclohexane acetic acid, wherein each (B) is independently selected from the group consisting of —H and C 1 -C 4 alkyl, and (B′) is —H or (α-Me), and p is zero or 1;
G is
wherein q, r and s are each independently zero or 1; p and t are each independently zero or 1; provided that at least one of q, r, s and t is 1;
and wherein either
A. (i) L is a linker selected from the group consisting of ε-D-Lys, ε-Lys, δ-D-Orn, δ-Orn, γ-aminobutyric acid, 8-aminooctanoic acid, 11-amino-undecanoic acid, 8-amino-3,6-dioxaoctanoic acid, 4-amino-4-carboxylic piperidine and (D-Lys-GlyLactam) 2 , and
(ii) the moieties Xaa 1 -Xaa 2 -Xaa 3 -(Xaa 4 ) p and (Xaa 1 ) q -(Xaa 2 ) r -(Xaa 3 ) s -(Xaa 4 ) t are different from one another, or
B. L is a linker selected from the group consisting of γ-aminobutyric acid, 8-aminooctanoic acid, 11-amino-undecanoic acid, 8-amino-3,6-dioxaoctanoic acid, 4-amino-4-carboxylic piperidine and (D-Lys-GlyLactam) 2 .
2. The method according to claim 1 , wherein the mammal is a human.
3. The method according to claim 1 , wherein the synthetic peptide amide is selected from the group consisting of the following compounds:
4. The method according to claim 1 , wherein the wherein the kappa opioid receptor-associated pain is inflammatory pain.
5. The method according to claim 4 , wherein the inflammatory pain is post injury inflammatory pain.
6. The method according to claim 1 , wherein the kappa opioid receptor-associated pain is pancreatic inflammatory pain.
7. The method according to claim 1 , wherein the kappa opioid receptor-associated pain is associated with inflammation.
8. The method according to claim 4 , wherein the inflammatory pain is associated with rheumatoid arthritis.
9. The method according to claim 1 , wherein the kappa opioid receptor-associated pain is associated with inflammatory swelling.
10. The method according to claim 1 , wherein the synthetic peptide amide is administered in a pharmaceutically acceptable excipient or carrier.
11. The method according to claim 1 , comprising administering to the mammal a composition comprising an effective amount of the synthetic peptide amide by injection, infusion or by a pump.
12. The method according to claim 11 , wherein the administration is intravenous, subcutaneous, intramuscular, intraperitoneal, intra-articular or intraocular.
13. The method according to claim 1 , wherein the administration is topical or local.
14. The method according to claim 13 , wherein the composition is administered intranasally, transdermally, intravaginally, intrarectally or by an intrapulmonary route.
15. The method according to claim 13 , wherein the composition is administered locally in an implant.
16. The method according to claim 13 , wherein the composition is administered topically to a mucosal surface selected from the group consisting of a mouth, an esophagus, a larynx, a bronchus and a nasal passage.
17. The method according to claim 13 , wherein the composition is administered topically to a vagina, a rectum or an anus.
18. The method according to claim 13 , wherein the composition is administered in a sustained-release formulation.
19. The method according to claim 13 , wherein the composition is administered in a tablet, a capsule, an ointment, a liquid, a powder or a gum.
20. The method according to claim 1 , comprising administering the composition orally.